Clinical trials: Lassa Fever
Healthy
Multiple Ascending Oral Dose 14-Day Trial of LHF-535 in Healthy Participants
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of a daily oral dose of LHF-535 administered for 14 days to healthy participants.
- Trial name
- NCT03993704
- Testing
- LHF-535
- Where
- Australia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Kineta Inc.
Lassa Fever
Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana
This is a randomized, blinded, placebo-controlled trial to evaluate the safety, tolerability and immunological profile of INO-4500 administered by intradermal (ID) injection followed by electroporation (EP) using CELLECTRA™ 2000…
- Trial name
- NCT04093076
- Testing
- INO-4500, CELLECTRA™ 2000
- Where
- Ghana
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Inovio Pharmaceuticals
Lassa Virus Infection
A Trial to Evaluate the Optimal Dose of MV-LASV (V182-001)
This is a randomized, placebo-controlled, single-center, dose finding phase I trial in healthy adult volunteer participants consisting of two phases, an unblinded dose escalation and an observer-blinded treatment phase.
- Trial name
- NCT04055454
- Testing
- MV-LASV
- Where
- Belgium
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Themis Bioscience GmbH
Lassa Fever
DMID 23-0015; Lassa Fever CVD 1000
This study proposes the evaluation of a novel, first-in-human Lassa fever vaccine based on the complete Lassa glycoprotein complex (GPC) antigen.
- Trial name
- NCT06546709
- Testing
- LASSARAB+ aPHAD-SEat 700rU, HDCV Comparator, LASSARAB+ aPHAD-SEat 1400rU
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Wilbur Chen, MD, MS
Lassa Fever
A Trial to Evaluate the Safety, Immunogenicity and the Optimal Dose of MOPEVAC-Las Vaccine Candidate Against Lassa Fever
Lassa fever is an acute viral disease belonging to the category of viral hemorrhagic fevers. It is endemic in West Africa. Outbreaks occur every year, and it is estimated that between 100 000 and 300 000 individuals are infected…
- Trial name
- FIRST-IN-MOP (NCT07833436)
- Testing
- Low dose MOPEVAC-Las vaccine, Intermediate dose MOPEVAC-Las vaccine, High dose MOPEVAC-Las vaccine
- Where
- France
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Lassa Fever
Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers
This is a randomized and double-blinded within study group, placebo-controlled trial to evaluate the safety, tolerability and immunological profile of INO-4500 administered by intradermal (ID) injection followed by…
- Trial name
- NCT03805984
- Testing
- INO-4500, CELLECTRA® 2000
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Inovio Pharmaceuticals
Lassa Fever
A Lassa Fever Vaccine Trial in Adults and Children Residing in West Africa
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults and Children Residing in West Africa
- Trial name
- NCT05868733
- Testing
- Day 1 Dose (2×106 pfu), Day 1 Dose (1×107 pfu), Day 1 Dose (2×10^5 pfu)
- Where
- 3 sites in Ghana, Liberia and 1 more
- Volunteers
- 530 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative
Lassa Fever, Lassa Virus Infection
A Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults in Good General Heath
A Phase 1 Randomized, Double-blinded, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults in Good General Health
- Trial name
- NCT04794218
- Testing
- rVSV∆G-LASV-GPC
- Where
- 4 sites in United States, Liberia
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative